Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
نویسندگان
چکیده
منابع مشابه
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution
The prevailing approach to addressing secondary drug resistance in cancer focuses on treating the resistance mechanisms at relapse. However, the dynamic nature of clonal evolution, along with potential fitness costs and cost compensations, may present exploitable vulnerabilities-a notion that we term "temporal collateral sensitivity." Using a combined pharmacological screen and drug resistance ...
متن کاملCollateral sensitivity to cisplatin in KB-8-5-11 drug-resistant cancer cells.
BACKGROUND KB-8-5-11 cells are a drug-resistant cervical cell model that overexpresses ABCB1 (P-glycoprotein). KB-8-5-11 has become sensitive to non-ABCB1 substrate cisplatin. Understanding the mechanism of collateral sensitivity to cisplatin may lead to biomarker discovery for platinum sensitivity in patients with cancer. MATERIALS AND METHODS A Taqman low-density array was used to character...
متن کاملExploiting poly(I:C) to induce cancer cell apoptosis
TLR3 belong to the Toll-like receptors family, it is mainly expressed on immune cells where it senses pathogen-associated molecular patterns and initiates innate immune response. TLR3 agonist poly(I:C) was developed to mimic pathogens infection and boost immune system activation to promote anti-cancer therapy. Accordingly, TLR agonists were included in the National Cancer Institute list of immu...
متن کاملCollateral sensitivity to methotrexate in cells resistant to adriamycin.
Chinese hamster ovary (CHO) cells, maintained and treated in log-phase growth, are extremely sensitive to Adniamycin but are very resistant to methotrexate-induced cell killing. The survival response to Adniamycin is biphasic, with the sensitive population showing a D0 of 0.08 pg/mI for 1 hr, while essen tially no cell killing is produced by methotrexate treatments of up to 500 @.tg/mI for eith...
متن کاملUse of collateral sensitivity networks to design drug cycling protocols that avoid resistance development.
New drug deployment strategies are imperative to address the problem of drug resistance, which is limiting the management of infectious diseases and cancers. We evolved resistance in Escherichia coli toward 23 drugs used clinically for treating bacterial infections and mapped the resulting collateral sensitivity and resistance profiles, revealing a complex collateral sensitivity network. On the...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Communications
سال: 2020
ISSN: 2041-1723
DOI: 10.1038/s41467-020-15596-z